Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521948 | 0.85 | EGLN3 (0.57) | EGLN3 | |
| SCHEMBL3521107 | 0.84 | EGLN3 (0.44) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3521075 | 0.81 | EGLN3 (0.52) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3757510 | 0.79 | EGLN3 (0.50) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3520286 | 0.79 | EGLN3 (0.57) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3543886 | 0.78 | EGLN3 (0.48) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3528513 | 0.78 | EGLN3 (0.46) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3527939 | 0.77 | EGLN3 (0.50) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3520565 | 0.77 | EGLN3 (0.50) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3531139 | 0.77 | EGLN3 (0.46) | EGLN3SMN1; SMN2ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101983384-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885SMN1; SMN2 3777/4885ALDH1A1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.